EVI1 overexpression in t(3;17) positive myeloid malignancies results from juxtaposition of EVI1 to the MSI2 locus at 17q22 by De Weer, An et al.
haematologica | 2008; 93(12) | 1903 |
EVI1 overexpression in t(3;17) positive myeloid
malignancies results from juxtaposition of EVI1
to the MSI2 locus at 17q22
An De Weer,1 Frank Speleman,1 Barbara Cauwelier,2 Nadine Van Roy,1 Nurten Yigit,1 
Bruno Verhasselt,3 Barbara De Moerloose,4 Yves Benoit,4 Lucien Noens,5 Dominik Selleslag,2
Eric Lippert,6 Stephanie Struski,7 Christian Bastard,8 Anne De Paepe,1 Peter Vandenberghe,9 
Anne Hagemeijer,9 Nicole Dastugue,10 and Bruce Poppe1 on behalf of the Groupe Français
de Cytogénétique Hématologique (GFCH)
1Centre for Medical Genetics Gent (CMGG), Ghent University Hospital, Ghent, Belgium; 2Department of Hematology,
Hospital St-Jan, Bruges, Belgium; 3Department of Clinical Chemistry, Microbiology and Immunology, Ghent University
Hospital, Ghent, Belgium; 4Department of Pediatric Hemato-Oncology, Ghent University Hospital, Ghent, Belgium;
5Department of Hematology, Ghent University Hospital, Ghent, Belgium; 6Laboratoire d’Hématologie, Groupe
Hospitalier Haut-Leveque – CHU de Bordeaux, Bordeaux, France; 7Laboratoire d’Hématologie, Hôpital de
Hautepierre, Strasbourg, France; 8Genetic laboratory and EMI 9906, Centre Henri Becquerel, Rouen, France; 9Centre
for Human Genetics, University of Leuven, Leuven, Belgium and 10Laboratoire d'Hématologie, Hôpital Purpan,
Toulouse, France
Brief Report
ABSTRACT
Chromosomal translocations involving the EVI1 locus are a recurrent finding in myeloid leukemia and are associated with poor progno-
sis. In this study, we performed a detailed molecular characterization of the recurrent translocation t(3;17)(q26;q22) in 13 hematolog-
ic malignancies. The EVI1 gene locus was rearranged in all 13 patients and was associated with EVI1 overexpression. In 9 out of 13
patients, the 17q breakpoints clustered in a 250 kb region on band 17q22 encompassing the MSI2 (musashi homologue 2) gene.
Expression analyses failed to demonstrate ectopic MSI2 expression or the presence of an MSI2/EVI1 fusion gene. In conclusion, we show
for the first time that the t(3;17) is indeed a recurrent chromosomal aberration in myeloid malignancies. In keeping with findings in other
recurrent 3q26 rearrangements, overexpression of the EVI1 gene appears to be the major contributor to leukemogenesis in patients with
a t(3;17).
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Introduction
The Ecotropic Viral Integration site 1 ( EVI1) gene is locat-
ed at chromosome band 3q26.2 and was identified as a
proto-oncogene by retroviral integration assays in mice.1
Rearrangements of the EVI1 locus are found in acute
myeloid leukemias (AML), myelodysplastic syndromes
(MDS) and chronic myeloid leukemias (CML). EVI1 gene
rearrangements account for approximately 5% of cytogenet-
ic abnormalities in these disease entities.2 Patients with an
EVI1 rearrangement have distinct clinical features, such as
marked hyperplasia with dysplasia of the megakaryocytes3
and, in some cases, hyperthrombocytosis.4
These 3q26 chromosomal aberrations confer an adverse
prognosis and contribute to ectopic expression of either full
length or truncated EVI1 transcripts, or to the formation of
EVI1 fusion genes.2 Common recurrent rearrangements
affecting the 3q26 locus include the inv(3)(q21q26) and the
translocation t(3;3)(q21;q26), in which EVI1 overexpression
is caused by juxtaposition of the EVI1 gene to enhancer ele-
ments of the Ribophorin (RPN) gene at 3q21 (5). EVI1 acti-
vation in the translocations t(3;12)(q26;p13) and
t(3;21)(q26;q22) is due to generation of the fusion genes
ETV6/EVI1 and RUNX1/EVI1 respectively.6,7
In addition to these well-characterized rearrangements,
the EVI1 locus is also involved in rare 3q26 aberrations such
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as the t(3;17)(q26;q22),8 the t(2;3)(p21~22;q26)9,10 and
the t(3;6)(q26;q25).11 For these EVI1 rearrangements,
the true recurrent nature and the partner chromosomes
involved, have not been analyzed in detail. Therefore,
we performed an in depth characterization of the 17q
breakpoints in 13 hematologic malignancies with a
t(3;17).
Design and Methods
Patients and cell lines 
In this multicenter retrospective study 13 leukemias
were included according to the following criteria; pres-
ence of a hematologic malignancy with a t(3;17) and
3q26 rearrangement. Karyotyping of diagnostic sam-
ples was performed according to standard procedures.
Several myeloid leukemia cell lines (K562 and U937)
and EVI1 rearranged cell lines (Kasumi-3 and UCSD-
AML1) were included as positive controls for EVI1
overexpression.12-15 The study was approved by the
ethics committee of the Ghent University Hospital
(2003/273). Patients’ characteristics and karyotypes are
described in Table 1. 
Fluorescence in situ hybridization
Dual-color fluorescence in situ hybridization (FISH)
with a dedicated EVI1 probe set (RP11-362K14, RP11-
82C9 and RP11-694D5) was performed on fixed nuclei
and/or metaphases of patients and cell lines.8 To char-
acterize the 17q breakpoints, eight different 17q
BAC/PAC probes over a region of 34.3 Mb on 17q
were selected from the UCSC (http://genome.ucsc.edu)
or Ensembl (http://ensembl.org) databases. The 17q and
EVI1 probes were all obtained from the Sanger
Wellcome Trust Institute, Hinxton, Cambridge (United
Kingdom). Position of the probes used and location of
translocation breakpoints is described in Figures 1
A–B.
Real-time quantitative RT-PCR
Total RNA was extracted from total bone marrow
samples or bone marrow leukocytes from 9 of 13
t(3;17) samples, from 4 myeloid cell lines, from bone
marrow of 3 patients without a hematologic disorder
and from 2 stem cell (CD34+) fractions, using the
miRNeasy kit (Qiagen, Belgium) according to the man-
ufacturer's recommendations. The cell lines and
CD34+ cells served as positive controls for the study of
EVI1 expression as well as for MSI2 expression. cDNA
was prepared from 2 µg of total RNA with the iScript
cDNA Synthesis Kit (Bio-Rad, Belgium) according to
the manufacturer’s descriptions.
Real-time quantitative RT-PCR (qRT-PCR) for the
EVI1 (exon 1b-2), cEVI1 (exon 8-9, primers located at
the 3’ end of the EVI1 gene to detect possible 5’ tran-
A. De Weer et al.
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Table 1 Patients’ characteristics, diagnosis, sex, age at diagnosis, G-banded karyotype.
Case Diagnosis† Percentage Age at Sex‡ Karyotype EVI1 Treatment Survival
of blasts in diagnosis
t(3;17) sample (years)
1 MDS 8 66 F 46,XX,t(3;17)(q26;q22)[12] - Supportive transfusions 7 years
2 CML-BC 48 25 M 46,XY,t(3;17)(q26;q22),t(9;22)(q34;q11.2)[18] ** AraC 10 months
3 CML-BC 45 69 M 46,XY,t(3;17)(q26;q22),t(9;22)(q34;q11.2), ** Hydrea 4 months
t(12;13)(p12;q13)[16]/47,sl,+8[2]
4 AML 22 6 M 45,XY,t(3;17)(q26;q22),-7[18] + AraC/VP16/M 6 months
5 MDS 7 58 M 47,XY,+3,del(3)(q25q27),t(3;17)(q26;q12), − AraC/VP16/D 15 months
del(6)(p23),-20,-21,+2mar[8]
6 CML-BC 59 65 M 46,XY,t(9;22)(q34;q11.2)[2]/ + Hydrea/6-M 4 months
46,sl,t(3;17)(q26;q22)[18]
7 AML 29 64 F 46,XX,t(3;17)(q26;q22),t(9;22)(q34;q11.2)[5]/ + ** **
46,XX[7]
8 AML 15 73 F 45,XX,t(3;17)(q26;q22),-7[6] − 6-T/G alive (2 years) ¶
9 AML 29 66 F 46,XX,t(3;17)(q26;q22)[10] ** AraC/D **
10 CML-BC 45 57 M 50,XY,t(3;9;22;17)(q26;q34;q11;q22), + AraC/D 9 months
+8,+der(9)t(3;9;22;17),
+10,+12,del(16)(q23)[15]
11 MDS 15 42 M 46,XY,t(3;17)(q26;q22)[21]/ − allo SC alive (3 years) ¶
46,sl,der(16)t(1;16)(q12;q12)[2]
12 AML 23 25 M 45,XY,t(3;17)(q26;q22),-7[2]/ + AraC/D 7 months
46,sl,+12[10]
13 AML 47 63 M 44,XY,t(2;3;17)(p21;q26;q22), ** AraC/I/CCNU/ 15 months
der(7)t(7;15)(p14;q15),der(10)t(10;16) Hydrea
(q26;q12~q13),-15,-16[25]
†MDS: myelodysplastic syndrome; CML: chronic myeloid leukemia; CML-BC: CML in blast crisis and AML: acute myeloid leukemia (according to FAB classification)
‡M: male and F: female. AraC : 1-β-D-arabinofuranosylcytosine; D: daunorubicin, VP16: etoposide; M: mitoxantrone; I: idarubicine; H: hydroxyurea; allo SC: allogenic
stem cell transplantation, 6-T = 6-thioguanine, G = gemtuzumab ozogamicin, 6-M = 6-mercaptopurine and CCNU = lomustine ¶ Survival time at publication ** No
data available +Positive for EVI1 overexpression with qRT-PCR. - Negative for EVI1 overexpression with qRT-PCR.
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script variants),16 MDS1/EVI1 (data not shown) and
MSI2 (primer pairs for exon 3 and 10) transcripts was
performed as previously described.8,17 For normaliza-
tion three housekeeping genes (RPL13A, YWHAZ and
HPRT1) were selected in view of their stability in bone
marrow samples as analyzed using the Genorm soft-
ware.17 The EVI1 overexpressing cell line Kasumi-3
carrying a t(3;7)(q26;q22) translocation12 was used as a
positive control.
RT-PCR
To investigate the possibility of MSI2/EVI1 fusion
gene formation, RT-PCR was performed. Based on the
known EVI1 breakpoint position in fusion genes and
the location of the MSI2 17q breakpoints, primers for
the second exon of EVI1 and the second exon of MSI2
were selected. For PCR analysis, the following touch-
down program was used: an initial denaturation step
at 94°C for 2 min, 12 cycles of 20 sec at 94°C, 15 sec at
the initial annealing temperature (Ta) 62°C (Ta-1°C for
each cycle ), 1 min at 72°C followed by 24 cycles of 40
sec at 94°C, 40 sec at 50°C, 30 sec at 72 °C and a final
extension step of 4 min at 72°C.
Results and Discussion
FISH analysis demonstrated a rearrangement of the
EVI1 locus in all samples. For 9 out of 13 leukemic sam-
ples, the 3q26 breakpoint was located 5’ (telomeric) of
the EVI1 gene which is in keeping with previous obser-
vations of 3q26 translocation breakpoint positions.8 In
3 out of 13 samples, the EVI1 breakpoint was located 3’
(centromeric) of the EVI1 gene and in case 5 the EVI1
breakpoint was located within the region correspon-
ding to the RP11-82C9 probe and could thus be located
either 5’, 3’ or within the EVI1 gene (Figure 1A).
In 9 of 13 patients the 17q breakpoint clustered in a
250 kb region on 17q22 harboring the MSI2 gene
(Figure 1B). For the remaining 3 cases, unique break-
points were detected in BAC clones RP11-386F9
(patient #5, 17q11.2), RP11-1094H24 (patient #3,
17q21.33) and in the PAC clone RP5-1171I10 (patient
#6, 17q22), respectively (data not shown). For patient
#13, the 17q breakpoint overlapping clone could not
be determined.
MSI2 plays a role in post-transcriptional gene regu-
lation and in maintaining stem cell status,18 and
involvement of MSI2 in myeloid leukemias has previ-
ously been reported in 2 CML patients, one of which
carried a MSI2/HOXA9 fusion gene.19 In our patient
series however, no MSI2/EVI1 fusion gene could be
detected in RT-PCR analysis. Given the opposite orien-
tation of MSI2 and EVI1 and the lack of karyotypic
evidence for complex rearrangements, this result was
indeed anticipated.20 Further study of a possible
MSI2/EVI1 fusion transcript was complicated by limit-
ed availability of patient sample. MSI2 rearrangements
have also been linked to CML and myeloproliferative
disorder disease progression.19,21,22 Interestingly, 2 out
of 9 patients with a MSI2 breakpoint were CML-BC
patients. 
Frequently observed secondary karyotypic changes
in CML include +8, i(17q), +19 and +Ph, but in some
occasions recurrent translocations and 3q26 rearrange-
ments are reported.23 We postulate that the t(3;17)
involving MSI2 is associated with CML as a secondary
aberration and could serve as a progression marker.
Real-time quantitative PCR with EVI1 and cEVI1
primers indicated that 5 out of 9 patients displayed
ectopic EVI1 expression (data not shown). In the remain-
ing 4 patients, no ectopic EVI1 expression could be
detected. In a previous study, we showed that the
majority of hematologic malignancies displaying a
The t(3;17) in myeloid malignancies targets EVI1 and MSI2
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Figure 1. Schematic overview of
the location of the 17q and 3q
probes and breakpoints. (A).
Physical map of the 3q26.2
probes used. The locations of the
EVI1 breakpoints in the 13
t(3;17) patients are indicated by
shaded boxes. (B). Location of
the 17q22 breakpoint for 9 out
of 13 patients. Vertical arrows
indicate location of the break-
points within the MSI2 gene. 
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rearrangement in the vicinity of EVI1 show ectopic
EVI1 expression.8 Therefore, we hypothesize that in
these 4 patients EVI1 expression could not be detected
because of the low blast counts in these samples.
Overexpression of the EVI1 oncogene conveys a poor
prognosis in AML and CML-BC.24 In our cohort,
patients without detectable EVI1 overexpression had
prolonged survival compared to the patients with EVI1
overexpression (Table 1). This enhanced prognosis
could in part be explained by the absence of a high
blast count which is indicative for an early stage of the
disease. Therefore the patient’s blast count might have
to be taken into account when addressing prognosis.
The exact cause of EVI1 overexpression is not
known, but in the inv(3)(q21q26) and the
t(3;3)(q21;q26) EVI1 is juxtaposed to the enhancer ele-
ments of the Ribophorin gene on chromosome band
3q21.5 Possibly, EVI1 overexpression in t(3;17)
leukemias is driven by enhancer elements located in
the vicinity of the MSI2 locus. 
We found no significant differences in MSI2 expres-
sion between MSI2 rearranged and MSI2 non-
rearranged t(3;13) hematologic malignancies (data not
shown). Expression of MSI2 in patients with a 17q
breakpoint in MSI2 is not straightforward. Due to the
translocation, a part of the MSI2 gene is separated
from its promoter. Therefore, we postulate that the
observed expression is due to residual expression from
the normal allele. 
No MSI2/EVI1 fusion gene could be detected, and
no significant MSI2 expression differences were found
between MSI2 rearranged and MSI2 non-rearranged
patients. Therefore, we have no evidence of a trans-
forming role of MSI2. Given the expression of MSI2 in
CD34+ cells (data not shown) it is feasible that the gene
is located in a region with open chromatin within the
genome. As these regions are more susceptible to dou-
ble strand DNA breaks, this could lead to increased
vulnerability of the MSI2 locus in chromosomal aber-
rations. Rearrangement and consecutive overexpres-
sion of EVI1 seem to be the main contributor to
tumorigenesis in t(3;17) patients. 
In conclusion, we confirm the t(3;17) as a recurrent
chromosomal aberration in myeloid malignancies,
consistently involving EVI1. We found that a distinct
subgroup (9 out of 13) shares a recurrent 17q break-
point region implicating the MSI2 gene, and postulate
that overexpression of the EVI1 gene is the major con-
tributor to leukemogenesis in patients with a t(3;17).
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